Kevin Joseph Fitzgerald sold $633k of ALNY
CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC.. 1,396 shares at an average of $453.27, traded Aug 18, 2025, filed Aug 19, 2025.
Score components
- +15RoleOfficer
- +20Trade size$633k at market
- 0Share of holdings soldSold 5.8% of holdings
- +15Cluster7 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000088, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 15, 2025 | AGrant or award Common Stock | +2,851 | $0.00 | $0 | 24,115 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock | -39 | $447.98 | $17k | 24,076 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock | -90 | $449.92 | $40k | 23,986 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock | -39 | $450.92 | $18k | 23,947 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock | -103 | $451.99 | $47k | 23,844 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock | -329 | $452.96 | $149k | 23,515 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock | -543 | $454.04 | $247k | 22,972 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock | -241 | $454.84 | $110k | 22,731 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock | -12 | $455.82 | $5,470 | 22,719 | Aug 19, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 26Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $418k 1,291 shares | -6% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $746k 2,309 shares | -6% | |
| 59Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $797k 2,468 shares | -4% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $948k 2,933 shares | -3% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.5M 4,713 shares | -20% | |
| 65Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $2.2M 6,799 shares | -6% | |
| 48Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $524k 1,598 shares | -4% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $1.1M 3,250 shares | -13% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.1M 3,492 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.